Recruiting

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

J2T-MC-KGAK - ClinicalTrials.gov - NCT04626297

The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).
How long will I be in the trial?
The study will last up to 32 weeks and may include up to 11 visits.
Email
Recruiting

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

J2T-MC-KGAK - ClinicalTrials.gov - NCT04626297

The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).
How long will I be in the trial?
The study will last up to 32 weeks and may include up to 11 visits.
Email

Key Requirements

Age :

18-55

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18-55

Sex

All

Participants must

Participants must have chronic atopic dermatitis

Participants must have had unsatisfactory results with existing medications applied to the skin

Participants must NOT

Participants must not have a history of anaphalaxis (severe, life threatening allergic reaction)

Participants must not have certain types of infection

Participants must not have other skin conditions or diseases that would interfere with the study

Participants must not have a history of certain types of cancers

Participants must not be pregnant or breastfeeding

Participants must have not received any tetanus-containing vaccine within approximately 5 years of baseline

Participants must have never received a meningitis vaccine (MCV), or have received only 1 prior MCV at least 4 years prior to baseline

Trial Summary

Conditions the trial is for

Atopic Dermatitis (Eczema)

What the trial is testing?

Lebrikizumab

Could I receive a Placebo?

yes

Enrollment Goal

240

Trial Dates

November 2020 - January 2022

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18-55

Sex

All

Participants must

Participants must have chronic atopic dermatitis

Participants must have had unsatisfactory results with existing medications applied to the skin

Participants must NOT

Participants must not have a history of anaphalaxis (severe, life threatening allergic reaction)

Participants must not have certain types of infection

Participants must not have other skin conditions or diseases that would interfere with the study

Participants must not have a history of certain types of cancers

Participants must not be pregnant or breastfeeding

Participants must have not received any tetanus-containing vaccine within approximately 5 years of baseline

Participants must have never received a meningitis vaccine (MCV), or have received only 1 prior MCV at least 4 years prior to baseline

Trial Summary

Conditions the trial is for

Atopic Dermatitis (Eczema)

What the trial is testing?

Lebrikizumab

Could I receive a Placebo?

yes

Enrollment Goal

240

Trial Dates

November 2020 - January 2022

Trial Phase

3

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Atopic Dermatitis (Eczema) Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?